US 2006/0216232 A1Published application

Compositions and methods for the treatment of tumor of hematopoietic origin

AssigneeGenentech, Inc.

InventorsWesley Chang, Frederic Sauvage, Dan Eaton, Allen Ebens, Gretchen Frantz, Hartmut Koeppen, Andrew Polson, Victoria Smith

Life of this patent

Estimating the term…

Abstract

The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.

Claims63

Dependent claims

A method of inhibiting the growth of a cell that expresses a protein having at least 80% amino acid sequence identity to:

(a) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 10 (SEQ ID NO:
6), FIG. 8 (SEQ ID NO:
8), FIG. 10 (SEQ ID NO:
10), FIG. 12 (SEQ ID NO:
12) and FIG. 22 (SEQ ID NO:
19);
(b) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 10 (SEQ ID NO:
6), FIG. 8 (SEQ ID NO:
8), FIG. 10 (SEQ ID NO:
10), FIG. 12 (SEQ ID NO:
12) and FIG. 22 (SEQ ID NO:
19), lacking its associated signal peptide;
(c) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 10 (SEQ ID NO:
6), FIG. 8 (SEQ ID NO:
8), FIG. 10 (SEQ ID NO:
10), FIG. 12 (SEQ ID NO:
12) and FIG. 22 (SEQ ID NO:
19), with its associated signal peptide;
(d) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 10 (SEQ ID NO:
6), FIG. 8 (SEQ ID NO:
8), FIG. 10 (SEQ ID NO:
10), FIG. 12 (SEQ ID NO:
12) and FIG. 22 (SEQ ID NO:
19), lacking its associated signal peptide;
(e) a polypeptide encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:
3), FIG. 5 (SEQ ID NO:
5), FIG. 7 (SEQ ID NO:
7), FIG. 9 (SEQ ID NO:
9), FIG. 11 (SEQ ID NO:
11) and FIG. 21 (SEQ ID NO:
18);
or
(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:
3), FIG. 5 (SEQ ID NO:
5), FIG. 7 (SEQ ID NO:
7), FIG. 9 (SEQ ID NO:
9), FIG. 11 (SEQ ID NO:
11) and FIG. 21 (SEQ ID NO:
18), said method comprising contacting said cell with an antibody, oligopeptide or organic molecule that binds to said protein, the binding of said antibody, oligopeptide or organic molecule to said protein thereby causing an inhibition of growth of said cell.

46 more elements

A method for treating or preventing a cell proliferative disorder associated with increased expression or activity of a protein having at least 80% amino acid sequence identity to:

(a) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 10 (SEQ ID NO:
6), FIG. 8 (SEQ ID NO:
8), FIG. 10 (SEQ ID NO:
10), FIG. 12 (SEQ ID NO:
12) and FIG. 22 (SEQ ID NO:
19);
(b) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 10 (SEQ ID NO:
6), FIG. 8 (SEQ ID NO:
8), FIG. 10 (SEQ ID NO:
10), FIG. 12 (SEQ ID NO:
12) and FIG. 22 (SEQ ID NO:
19), lacking its associated signal peptide;
(c) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 10 (SEQ ID NO:
6), FIG. 8 (SEQ ID NO:
8), FIG. 10 (SEQ ID NO:
10), FIG. 12 (SEQ ID NO:
12) and FIG. 22 (SEQ ID NO:
19), with its associated signal peptide;
(d) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 10 (SEQ ID NO:
6), FIG. 8 (SEQ ID NO:
8), FIG. 10 (SEQ ID NO:
10), FIG. 12 (SEQ ID NO:
12) and FIG. 22 (SEQ ID NO:
19), lacking its associated signal peptide;
(e) a polypeptide encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:
3), FIG. 5 (SEQ ID NO:
5), FIG. 7 (SEQ ID NO:
7), FIG. 9 (SEQ ID NO:
9), FIG. 11 (SEQ ID NO:
11) and FIG. 21 (SEQ ID NO:
18);
or
(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:
3), FIG. 5 (SEQ ID NO:
5), FIG. 7 (SEQ ID NO:
7), FIG. 9 (SEQ ID NO:
9), FIG. 11 (SEQ ID NO:
11) and FIG. 21 (SEQ ID NO:
18), said method comprising administering to a subject in need of such treatment an effective amount of an antagonist of said protein, thereby effectively treating or preventing said cell proliferative disorder.

46 more elements

A method for inhibiting the growth of a cell, wherein the growth of said cell is at least in part dependent upon a growth potentiating effect of a protein having at least 80% amino acid sequence identity to:

(a) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 10 (SEQ ID NO:
6), FIG. 8 (SEQ ID NO:
8), FIG. 10 (SEQ ID NO:
10), FIG. 12 (SEQ ID NO:
12) and FIG. 22 (SEQ ID NO:
19);
(b) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 10 (SEQ ID NO:
6), FIG. 8 (SEQ ID NO:
8), FIG. 10 (SEQ ID NO:
10), FIG. 12 (SEQ ID NO:
12) and FIG. 22 (SEQ ID NO:
19), lacking its associated signal peptide;
(c) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 10 (SEQ ID NO:
6), FIG. 8 (SEQ ID NO:
8), FIG. 10 (SEQ ID NO:
10), FIG. 12 (SEQ ID NO:
12) and FIG. 22 (SEQ ID NO:
19), with its associated signal peptide;
(d) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 10 (SEQ ID NO:
6), FIG. 8 (SEQ ID NO:
8), FIG. 10 (SEQ ID NO:
10), FIG. 12 (SEQ ID NO:
12) and FIG. 22 (SEQ ID NO:
19), lacking its associated signal peptide;
(e) a polypeptide encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:
3), FIG. 5 (SEQ ID NO:
5), FIG. 7 (SEQ ID NO:
7), FIG. 9 (SEQ ID NO:
9), FIG. 11 (SEQ ID NO:
1) and FIG. 21 (SEQ ID NO:
18);
or
(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:
3), FIG. 5 (SEQ ID NO:
5), FIG. 7 (SEQ ID NO:
7), FIG. 9 (SEQ ID NO:
9), FIG. 11 (SEQ ID NO:
11) and FIG. 21 (SEQ ID NO:
18), said method comprising contacting said protein with an antibody, oligopeptide or organic molecule that binds to said protein, there by inhibiting the growth of said cell.

46 more elements

An isolated antibody that binds to a polypeptide having at least 80% amino acid sequence identity to:

(a) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6), FIG. 8 (SEQ ID NO:
8), FIG. 10 (SEQ ID NO:
10), FIG. 12 (SEQ ID NO:
12) and FIG. 22 (SEQ ID NO:
19);
(b) the polypeptide selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6), FIG. 8 (SEQ ID NO:
8), FIG. 10 (SEQ ID NO:
10), FIG. 12 (SEQ ID NO:
12) and FIG. 22 (SEQ ID NO:
19), lacking its associated signal peptide;
(c) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6), FIG. 8 (SEQ ID NO:
8), FIG. 10 (SEQ ID NO:
10), FIG. 12 (SEQ ID NO:
12) and FIG. 22 (SEQ ID NO:
19), with its associated signal peptide;
(d) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6), FIG. 8 (SEQ ID NO:
8), FIG. 10 (SEQ ID NO:
10), FIG. 12 (SEQ ID NO:
12) and FIG. 22 (SEQ ID NO:
19), lacking its associated signal peptide;
(e) a polypeptide encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:3), FIG. 5 (SEQ ID NO:
5), FIG. 7 (SEQ ID NO:
7), FIG. 9 (SEQ ID NO:
9), FIG. 11 (SEQ ID NO:
11) and FIG. 21 (SEQ ID NO:
18);
or
(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:3), FIG. 5 (SEQ ID NO:
5), FIG. 7 (SEQ ID NO:
7), FIG. 11 (SEQ ID NO:
11) and FIG. 21 (SEQ ID NO:
18).

43 more elements

An isolated antibody that binds to a polypeptide having:

(a) the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6), FIG. 8 (SEQ ID NO:
8), FIG. 10 (SEQ ID NO:
10), FIG. 12 (SEQ ID NO:
12) and FIG. 22 (SEQ ID NO:
19);
(b) the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6), FIG. 8 (SEQ ID NO:
8), FIG. 10 (SEQ ID NO:
10), FIG. 12 (SEQ ID NO:
12) and FIG. 22 (SEQ ID NO:
19), lacking its associated signal peptide sequence;
(c) an amino acid sequence of an extracellular domain of the polypeptide selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6), FIG. 8 (SEQ ID NO:
8), FIG. 10 (SEQ ID NO:
10), FIG. 12 (SEQ ID NO:
12) and FIG. 22 (SEQ ID NO:
19), with its associated signal peptide sequence;
(d) an amino acid sequence of an extracellular domain of the polypeptide selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 6 (SEQ ID NO:
6), FIG. 8 (SEQ ID NO:
8), FIG. 10 (SEQ ID NO:
10), FIG. 12 (SEQ ID NO:
12) and FIG. 22 (SEQ ID NO:
19), lacking its associated signal peptide sequence;
(e) an amino acid sequence encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:3), FIG. 5 (SEQ ID NO:
5), FIG. 7 (SEQ ID NO:
7), FIG. 9 (SEQ ID NO:
9), FIG. 11 (SEQ ID NO:
11) and FIG. 21 (SEQ ID NO:
18);
or
(f) an amino acid sequence encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:3), FIG. 5 (SEQ ID NO:
5), FIG. 7 (SEQ ID NO:
7), FIG. 9 (SEQ ID NO:
9), FIG. 11 (SEQ ID NO:
11) and FIG. 21 (SEQ ID NO:
18).

44 more elements

Dependencies are inferred from the claim text.

Facts

Application: 11/315,529Filed 21 Dec 2005
Priority: WO PCT/US04/3826216 Nov 2004
Published: 28 Sep 2006
Term ends: Not estimatedThe source records don’t support an estimate.

Classification18 codes

C07K 14/4748
Not used: tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
A61K 47/68031
Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates: the drug being an auristatin
A61K 47/68033
Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates: the drug being a maytansine
A61K 47/6867
The antibody targeting a determinant of a tumour cell: the tumour determinant being from a cell of a blood cancer

Family

Application11/020,508Continuation in part · filed 21 Dec 2004
Application11/315,529Continuation in part · filed 21 Dec 2005
US 2005/0226869 A1Published application
US 7,888,478 B2Related patent
US 2006/0216232 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.

A method of inhibiting the growth of a cell that expresses a protein having at least 80% amino acid sequence identity to:

(a) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 10 (SEQ ID NO:
6), FIG. 8 (SEQ ID NO:
8), FIG. 10 (SEQ ID NO:
10), FIG. 12 (SEQ ID NO:
12) and FIG. 22 (SEQ ID NO:
19);
(b) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 10 (SEQ ID NO:
6), FIG. 8 (SEQ ID NO:
8), FIG. 10 (SEQ ID NO:
10), FIG. 12 (SEQ ID NO:
12) and FIG. 22 (SEQ ID NO:
19), lacking its associated signal peptide;
(c) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 10 (SEQ ID NO:
6), FIG. 8 (SEQ ID NO:
8), FIG. 10 (SEQ ID NO:
10), FIG. 12 (SEQ ID NO:
12) and FIG. 22 (SEQ ID NO:
19), with its associated signal peptide;
(d) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO:
2), FIG. 4 (SEQ ID NO:
4), FIG. 10 (SEQ ID NO:
6), FIG. 8 (SEQ ID NO:
8), FIG. 10 (SEQ ID NO:
10), FIG. 12 (SEQ ID NO:
12) and FIG. 22 (SEQ ID NO:
19), lacking its associated signal peptide;
(e) a polypeptide encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:
3), FIG. 5 (SEQ ID NO:
5), FIG. 7 (SEQ ID NO:
7), FIG. 9 (SEQ ID NO:
9), FIG. 11 (SEQ ID NO:
11) and FIG. 21 (SEQ ID NO:
18);
or
(f) a polypeptide encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO:
1), FIG. 3 (SEQ ID NO:
3), FIG. 5 (SEQ ID NO:
5), FIG. 7 (SEQ ID NO:
7), FIG. 9 (SEQ ID NO:
9), FIG. 11 (SEQ ID NO:
11) and FIG. 21 (SEQ ID NO:
18), said method comprising contacting said cell with an antibody, oligopeptide or organic molecule that binds to said protein, the binding of said antibody, oligopeptide or organic molecule to said protein thereby causing an inhibition of growth of said cell.

46 more elements

Facts

Application

11/315,529Filed 21 Dec 2005

Priority

WO PCT/US04/3826216 Nov 2004

Published

28 Sep 2006

Term ends

Not estimatedThe source records don’t support an estimate.

Classification18 codes

C07K 14/4748
Not used: tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
A61K 47/68031
Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates: the drug being an auristatin
A61K 47/68033
Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates: the drug being a maytansine
A61K 47/6867
The antibody targeting a determinant of a tumour cell: the tumour determinant being from a cell of a blood cancer